ClinicalTrials.gg
Not yet recruitingNCT07294391Updated Dec 19, 2025

The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke

A Phase 2 interventional study of Human serum albumin infusion 20% in Acute Ischemic Stroke From Large Vessel Occlusion, sponsored by Tianjin Huanhu Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Tianjin Huanhu Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Ischemic Stroke · Tianjin Huanhu Hospital.

Started
2025
the only one that year
Phase 2
2 of 12
2 open now
Primary completion
2026-12
later than 6 of 10 live
Registered
11th of 12
by date

Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, this one is the only one that started in 2025, is one of 2 in phase 2, reaches primary completion later than 6 of the 10 other live ones, and was the 11th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

10 of the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, or all of them as a file.
02

Study summary

Albumin-assisted therapy has demonstrated good safety and potential neuroprotective effects following mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we are conducting a Phase IIa clinical trial of intra-arterial albumin administration combined with mechanical thrombectomy in patients with acute ischemic stroke. This is a double-center, prospective, open-label, endpoint-blinded, randomized controlled trial designed to preliminarily assess the efficacy and safety of intra-arterial infusion of 20% human albumin after successful recanalization in patients with acute ischemic stroke caused by anterior circulation large-vessel occlusion who undergo mechanical thrombectomy. A total of 60 patients will be enrolled and randomized in a 1:1 ratio by dynamic minimization into two groups: the albumin group (0.6 g/kg of 20% human albumin solution plus mechanical thrombectomy) and the control group (mechanical thrombectomy alone).

The primary objective of this study is to preliminarily evaluate whether intra-arterial infusion of 0.6 g/kg of 20% human albumin via the internal carotid artery immediately after achieving successful recanalization (eTICI ≥ 2b) can reduce infarct volume compared with mechanical thrombectomy alone in patients with anterior circulation large-vessel occlusion who undergo standard mechanical thrombectomy. The secondary objective is to assess the safety and feasibility of intra-arterial infusion of 0.6 g/kg of 20% human albumin immediately after successful recanalization in this patient population.

03

Conditions studied

  • Acute Ischemic Stroke From Large Vessel Occlusion

Browse trials for

Keywords

  • Acute ischemic stroke
  • large vessel occlusion
  • mechanical thrombectomy
  • albumin
  • neuroprotection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age ≥ 18 years; 2.ICA or MCA-M1 occlusion, confirmed by preoperative CTA/MRA/DSA. ICA occlusion can be cervical or intracranial, with or without tandem MCA lesions; Treated with EVT resulting in recanalization ((expanded Thrombolysis in Cerebral Infarction [eTICI] 2b-3); 3.Baseline NIHSS scores ≥ 6; 4.Baseline ASPECTS ≥6 on non-contrast CT; 5.The time from stroke onset/last seen well to arterial puncture is within 24 hours; 6.No significant pre-stroke disability (pre-stroke mRS ≤2); 7.Signed from the patient or the legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • 1.Presence of intracranial hemorrhage on head CT or MRI; 2.Midline shift with significant mass effect on head CT or MRI; 3.History of heart failure or severe cardiovascular disease, including but not limited to pulmonary hypertension, pericardial effusion, etc; 4.Arrhythmia accompanied by hemodynamic instability; 5.Symptoms or electrocardiographic evidence of acute myocardial infarction upon admission; 6.Acute or chronic renal failure (serum creatinine >2.0 mg/dL); 7.Severe anemia (hematocrit \<32%); 8.Known allergy to albumin or blood products; 9.Pregnant women; 10.Persistent blood pressure ≥180/100 mmHg prior to albumin infusion; 11.Concurrent participation in another clinical trial; 12. of less than 3 months; 13.Coexisting severe pulmonary diseases such as , pulmonary fibrosis, pleural effusion, pulmonary hypertension, or acute respiratory distress syndrome; 14.Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Albumin Group

    Subjects assigned to the albumin treatment group after achieving successful recanalization (eTICI ≥ 2b) confirmed by DSA post-thrombectomy will receive a 20% human albumin solution at a dose of 0.60 g/kg. The solution will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes. Vital signs and potential infusion-related reactions must be closely monitored throughout the procedure.

    Drug: Human serum albumin infusion 20%

  • No intervention
    Control Group

    Subjects in the control group who have achieved successful recanalization (eTICI ≥ 2b) as confirmed by DSA following mechanical thrombectomy will not receive the investigational infusion and will undergo standard medical management only.

Interventions

  • DrugAlbumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    20% human albumin solution at a dose of 0.60 g/kg will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes.

06

What researchers measure

Primary outcomes

  1. Growth in infarct volume at 24 (±6) hours after randomization compared to baseline

    MRI-DWI

    Time frame: at 24 (±6) hours after randomization

Secondary outcomes

  1. Proportion of favorable functional outcome at 90 (±14) days, defined as mRS 0-2

    mRS

    Time frame: at 90 (±14) day after randomizatio

  2. Infarct volume at 24 (±6) hours

    MRI-DWI

    Time frame: at 24 (±6) hours after randomization

  3. Proportion of excellent functional at 90 (±14) days, defined as mRS 0-1

    mRS

    Time frame: at 90 (±14) day after randomization

  4. mRS score at 90 (±14) days

    mRS

    Time frame: at 90 (±14) days after randomization

  5. Vessel recanalization at 24 (±6) hours

    CTA or MRA or DSA

    Time frame: at 24 (±6) hours after randomization

  6. NIHSS score at 24 (±6) hours

    NIHSS

    Time frame: at 24 (±6) hours after randomization

  7. NIHSS score at 7 (±1) days/at discharge

    NIHSS

    Time frame: at 7 (±1) days/at discharge after randomization

  8. EQ-5D-5L at 90 (±14) days

    EQ-5D-5L

    Time frame: at 90 (±14) days after randomization

  9. Proportion of Barthel Index ≥95 at 90 (±14) days

    Barthel Index

    Time frame: at 90 (±14) days after randomization

  10. Incidence of all-cause death within 90 (±14) days

    all-cause death

    Time frame: at 90 (±14) days after randomization

  11. Incidence of symptomatic intracranial hemorrhage within 24 (±6) hours

    according to the modified Heidelberg Bleeding Classification

    Time frame: at 24 (±6) hours after randomization

  12. Incidence of intracranial hemorrhage within 24 (±6) hours

    all-cause

    Time frame: at 24 (±6) hours after randomization

  13. Incidence of serious adverse events within 90 (±14) days

    serious adverse events

    Time frame: at 90 (±14) days after randomization

  14. Incidence of adverse events within 90 (±14) days

    adverse events

    Time frame: at 90 (±14) days after randomization

  15. Proportion of early neurological deterioration at 24 hours

    defined as ≥ 4-point increase in NIHSS score from baseline

    Time frame: at 24 hours after randomization

  16. Proportion of severe disability at 90 (±14) days

    defined as mRS 4-6

    Time frame: at 90 (±14) days after randomization

  17. Incidence of albumin infusion-associated adverse event within 24 (± 6) hours

    albumin infusion-associated adverse event

    Time frame: at 24 (± 6) hours after randomization

Other outcomes

  1. Blood levels of albumin and BNP at 24 (±6) hours after randomization

    albumin and BNP

    Time frame: at 24 (±6) hours after randomization

  2. Blood levels of albumin and BNP at 7 (±1) days after randomization or at discharge (whichever occurs first)

    albumin and BNP

    Time frame: at 7 (±1) days after randomization or at discharge (whichever occurs first)

  3. The along the perivascular space (ALPS) index at 24 (±6) hours after randomization

    along the perivascular space index

    Time frame: at 24 (±6) hours after randomization

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 11 months later.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 11 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 19, 2025
StartEst.
Dec 10, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07294391
Lead sponsor
Tianjin Huanhu Hospital
Collaborators
The First Hospital of Qinhuangdao
Responsible party
Ming Wei (PhD, Tianjin Huanhu Hospital) — Principal investigator
First posted
Dec 19, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 19, 2025

Study contacts

Ming Wei PhD, PhD
Contact
weiming@tmu.edu.cn
86+13502182903
Du, PhD
Contact
dkj1024@163.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion